HO-1 Cancer Research Results

HO-1, HMOX1: Click to Expand ⟱
Source:
Type:
(Also known as Hsp32 and HMOX1)
HO-1 is the common abbreviation for the protein (heme oxygenase‑1) produced by the HMOX1 gene.
HO-1 is an enzyme that plays a crucial role in various cellular processes, including the breakdown of heme, a toxic molecule. Research has shown that HO-1 is involved in the development and progression of cancer.
-widely regarded as having antioxidant and cytoprotective effects
-The overall activity of HO‑1 helps to reduce the pro‐oxidant load (by degrading free heme, a pro‑oxidant) and to generate molecules (like bilirubin) that can protect cells from oxidative damage

Studies have found that HO-1 is overexpressed in various types of cancer, including lung, breast, colon, and prostate cancer. The overexpression of HO-1 in cancer cells can contribute to their survival and proliferation by:
  Reducing oxidative stress and inflammation
  Promoting angiogenesis (the formation of new blood vessels)
  Inhibiting apoptosis (programmed cell death)
  Enhancing cell migration and invasion
When HO-1 is at a normal level, it mainly exerts an antioxidant effect, and when it is excessively elevated, it causes an accumulation of iron ions.

A proper cellular level of HMOX1 plays an antioxidative function to protect cells from ROS toxicity. However, its overexpression has pro-oxidant effects to induce ferroptosis of cells, which is dependent on intracellular iron accumulation and increased ROS content upon excessive activation of HMOX1.

-Curcumin   Activates the Nrf2 pathway leading to HO‑1 induction; known for its anti‑inflammatory and antioxidant effects.
-Resveratrol  Induces HO‑1 via activation of SIRT1/Nrf2 signaling; exhibits antioxidant and cardioprotective properties.
-Quercetin   Activates Nrf2 and related antioxidant pathways; contributes to anti‑oxidative and anti‑inflammatory responses.
-EGCG     Promotes HO‑1 expression through activation of the Nrf2/ARE pathway; also exhibits anti‑inflammatory and anticancer properties.
-Sulforaphane One of the most potent natural HO‑1 inducers; triggers Nrf2 nuclear translocation and upregulates a battery of phase II detoxifying enzymes.
-Luteolin    Induces HO‑1 via Nrf2 activation; may also exert anti‑inflammatory and neuroprotective effects in various cell models.
-Apigenin   Has been reported to induce HO‑1 expression partly via the MAPK and Nrf2 pathways; also known for anti‑inflammatory and anticancer activities.
Scientific Papers found: Click to Expand⟱
256- AL,  doxoR,    Allicin Overcomes Doxorubicin Resistance of Breast Cancer Cells by Targeting the Nrf2 Pathway
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
NRF2↓, HO-1↓, p‑Akt↓,
1235- ALA,  Cisplatin,    α-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway
- in-vitro, Nor, HEI-OC1 - ex-vivo, NA, NA
ROS↑, HO-1↓, *toxicity↓, chemoP↑, *ROS↓, *HO-1↑, *SOD1↑, *NRF2↑,
4992- ART/DHA,    Dihydroartemisinin Increases the Sensitivity of Acute Myeloid Leukemia Cells to Cytarabine via the Nrf2/HO-1 Anti-Oxidant Signaling Pathway
- in-vitro, AML, HL-60
Apoptosis↑, Diff↑, ROS↓, HO-1↓, NRF2∅,
4993- ART/DHA,    Dihydroartemisinin inhibits galectin-1–induced ferroptosis resistance and peritoneal metastasis of gastric cancer via the Nrf2–HO-1 pathway
- vitro+vivo, GC, NA
Ferroptosis↑, NRF2↓, HO-1↓, PI3K↓, Akt↓, TumMeta↓,
2296- Ba,    The most recent progress of baicalein in its anti-neoplastic effects and mechanisms
- Review, Var, NA
CDK1↓, Cyc↓, p27↑, P21↑, P53↑, TumCCA↑, TumCI↓, MMP2↓, MMP9↓, E-cadherin↑, N-cadherin↓, Vim↓, LC3A↑, p62↓, p‑mTOR↓, PD-L1↓, CAFs/TAFs↓, VEGF↓, ROCK1↓, Bcl-2↓, Bcl-xL↓, BAX↑, ROS↑, cl‑PARP↑, Casp3↑, Casp9↑, PTEN↑, MMP↓, Cyt‑c↑, Ca+2↑, PERK↑, IRE1↑, CHOP↑, Copper↑, Snail↓, Vim↓, Twist↓, GSH↓, NRF2↓, HO-1↓, GPx4↓, XIAP↓, survivin↓, DR5↑,
5536- BBM,    Regulation of Cell-Signaling Pathways by Berbamine in Different Cancers
- Review, Var, NA
JAK↝, STAT3↓, p‑CaMKII ↓, TGF-β↑, Smad1↑, ChemoSen↑, RadioS↑, TumCI↓, TumCMig↓, ROS↑, NRF2↓, SOD2↓, GPx1↓, HO-1↓,
5551- BBM,    Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF-κB Axis
- vitro+vivo, Bladder, NA
tumCV↓, TumCP↓, TumCCA↑, P21↑, p27↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, EMT↓, TumMeta↓, p65↓, p‑p65↓, IKKα↓, NF-kB↑, ROS↑, NRF2↓, HO-1↓, SOD2↓, GPx1↓, Bax:Bcl2↑, TumVol↓,
1392- BBR,    Based on network pharmacology and experimental validation, berberine can inhibit the progression of gastric cancer by modulating oxidative stress
- in-vitro, GC, AGS - in-vitro, GC, MKN45
TumCG↓, TumCMig↓, ROS↑, MDA↑, SOD↓, NRF2↓, HO-1↓, Hif1a↓, EMT↓, Snail↓, Vim↓,
1390- BBR,  Rad,    Berberine Inhibited Radioresistant Effects and Enhanced Anti-Tumor Effects in the Irradiated-Human Prostate Cancer Cells
- in-vitro, Pca, PC3
RadioS↑, Apoptosis↑, ROS↑, eff↑, BAX↑, Casp3↑, P53↑, p38↑, JNK↑, Bcl-2↓, ERK↓, HO-1↓,
2756- BetA,    Betulinic acid inhibits growth of hepatoma cells through activating the NCOA4-mediated ferritinophagy pathway
- in-vitro, HCC, HUH7 - in-vitro, HCC, H1299
TumCP↓, ROS↑, antiOx↓, TumCG↓, TumCMig↓, NRF2↓, GPx4↓, HO-1↓, NCOA4↑, FTH1↓, Ferritin↑, Ferroptosis↑, GSH↓, MDA↓,
5690- BJ,  BRU,    Brusatol: A potential sensitizing agent for cancer therapy from Brucea javanica
- Review, Var, NA
NRF2↓, TumCG↓, ChemoSen↑, ROS↑, NF-kB↓, Akt↓, mTOR↓, TumCCA↑, Apoptosis↑, PARP↑, Casp↑, P53↓, Bcl-2↓, PI3K↓, JAK2↓, EMT↓, p27↑, ROCK1↓, MMP2↓, MMP9↓, NRF2↓, AntiTum↑, HO-1↓, NQO1↓, VEGF↓, MRP1↓, RadioS↑, PhotoS↑, toxicity↝,
5680- BML,    Anticancer properties of bromelain: State-of-the-art and recent trends
- Review, Var, NA
*Inflam↓, *Bacteria↓, *Pain↓, *Diar↓, *Wound Healing↑, ERK↓, JNK↓, XIAP↓, HSP27↓, β-catenin/ZEB1↓, HO-1↓, lipid-P↓, ACSL4↑, ROS↑, SOD↑, Catalase↓, GSH↓, MDA↓, Casp3↓, Casp9↑, DNAdam↑, Apoptosis↑, NF-kB↓, P53↑, MAPK↓, APAF1↑, Cyt‑c↓, CD44↓, Imm↑, ATG5↑, LC3I↑, Beclin-1↑, IL2↓, IL4↓, IFN-γ↓, COX2↓, iNOS↓, ChemoSen↑, RadioS↑, Dose↝, other↓,
6017- CGA,    Therapeutic Potential of Chlorogenic Acid in Chemoresistance and Chemoprotection in Cancer Treatment
- Review, Var, NA
AntiCan↑, *chemoP↑, TNF-α↓, COX2↓, IL6↓, eff↑, PD-L1↓, *cognitive↓, *Aβ↓, *TAC↑, *SOD↑, *eff↑, *eff↑, ChemoSen↑, tumCV↓, Apoptosis↑, ERK↓, chemoP↑, *GPx↑, *GSTs↑, *GSH↑, *SOD↑, *Catalase↑, *ROS↓, *lipid-P↓, *MDA↓, *Casp3↓, *HO-1↓, cardioP↑, radioP↑,
6010- CGA,    The Biological Activity Mechanism of Chlorogenic Acid and Its Applications in Food Industry: A Review
- Review, Nor, NA
*antiOx↑, *hepatoP↑, *RenoP↑, AntiTum↑, *glucose↝, *Inflam↓, *neuroP↑, *ROS↓, *Keap1↓, *NRF2↑, *SOD↑, *Catalase↑, *GPx↑, *GSH↑, *MDA↓, *p‑ERK↑, *GRP78/BiP↑, *CHOP↑, *GRP94↑, *Casp3↓, *Casp9↓, *HGF/c-Met↑, *TNF-α↓, *TLR4↓, *MAPK↓, *IL1β↓, *iNOS↓, TCA↓, Glycolysis↓, Bcl-2↓, BAX↑, MAPK↑, JNK↑, CSCs↓, Nanog↓, SOX2↓, CD44↓, OCT4↓, P53↑, P21↑, *SOD1↑, *AGEs↓, *GLUT2↑, *HDL↑, *Fas↓, *HMG-CoA↓, *NF-kB↓, *HO-1↓, *COX2↓, *TLR4↓, *BioAv↑, *BioAv↝, TumCP↓, TumCMig↓, TumCI↓,
2590- CHr,    Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the ERK/Nrf2 signaling pathway
- in-vitro, GBM, T98G - in-vitro, GBM, U251 - in-vitro, GBM, U87MG
TumCP↓, TumCMig↓, TumCI↓, NRF2↓, HO-1↓, NADPH↓, ERK↓,
2591- CHr,  doxoR,    Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway
- in-vitro, HCC, Bel-7402
NRF2↓, ChemoSen↑, HO-1↓,
2785- CHr,    Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin
- Review, Var, NA
*NF-kB↓, *COX2↓, *iNOS↓, angioG↓, TOP1↓, HDAC↓, TNF-α↓, IL1β↓, cardioP↑, RenoP↑, neuroP↑, LDL↓, BioAv↑, eff↑, cycD1/CCND1↓, hTERT/TERT↓, MMP-10↓, Akt↓, STAT3↓, VEGF↓, EGFR↓, Snail↓, Slug↓, Vim↓, E-cadherin↑, eff↑, TET1↑, ROS↑, mTOR↓, PPARα↓, ER Stress↑, Ca+2↑, ERK↓, MMP↑, Cyt‑c↑, Casp3↑, HK2↓, NRF2↓, HO-1↓, MMP2↓, MMP9↓, Fibronectin↓, GRP78/BiP↑, XBP-1↓, p‑eIF2α↑, *AST↓, ALAT↓, ALP↓, LDH↓, COX2↑, Bcl-xL↓, IL6↓, PGE2↓, iNOS↓, DNAdam↑, UPR↑, Hif1a↓, EMT↓, Twist↓, lipid-P↑, CLDN1↓, PDK1↓, IL10↓, TLR4↓, NOTCH1↑, PARP↑, Mcl-1↓, XIAP↓,
1410- CUR,    Curcumin induces ferroptosis and apoptosis in osteosarcoma cells by regulating Nrf2/GPX4 signaling pathway
- vitro+vivo, OS, MG63
tumCV↓, Apoptosis↑, TumCG↓, NRF2↓, GPx4↓, HO-1↓, xCT↓, ROS↑, MDA↑, GSH↓,
1863- dietFMD,  Chemo,    Effect of fasting on cancer: A narrative review of scientific evidence
- Review, Var, NA
eff↑, ChemoSideEff↓, ChemoSen↑, Insulin↓, HDAC↓, IGF-1↓, STAT5↓, BG↓, MAPK↓, HO-1↓, ATG3↑, Beclin-1↑, p62↑, SIRT1↑, LAMP2↑, OXPHOS↑, ROS↑, P53↑, DNAdam↑, TumCD↑, ATP↑, Treg lymp↓, M2 MC↓, CD8+↑, Glycolysis↓, GutMicro↑, GutMicro↑, Warburg↓, Dose↝,
1847- dietFMD,  VitC,    Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers
- in-vitro, PC, PANC1
TumCG↓, ChemoSen↑, eff↑, HO-1↓, Ferritin↓, Iron↑, ROS↑, TumCD↑, IGF-1↓, eff↓, eff↓,
1846- dietFMD,  VitC,    A fasting-mimicking diet and vitamin C: turning anti-aging strategies against cancer
- Study, Var, NA
TumCG↓, ChemoSen↑, ChemoSideEff↓, ROS↑, Fenton↑, H2O2↑, eff↑, HO-1↓, DNAdam↑, eff↑,
1859- dietFMD,  Chemo,    Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity
- in-vitro, BC, 4T1 - in-vivo, Melanoma, B16-BL6
CLP↑, CD8+↑, TumCG↓, HO-1↓, TILs↑,
1626- dietSTF,  dietFMD,    When less may be more: calorie restriction and response to cancer therapy
- Review, Var, NA
CRM↑, ChemoSen↑, RadioS↑, eff↑, eff↑, IGF-1↓, TumCG↓, AMPK↑, eff↑, ChemoSen↑, RadioS↑, ROS↑, DNAdam↑, eff↑, HO-1↓,
4990- Dipy,    Characterization of dipyridamole as a novel ferroptosis inhibitor and its therapeutic potential in acute respiratory distress syndrome management
- in-vivo, Nor, NA
*Ferroptosis↓, *HO-1↓, SOD1↑,
5007- DSF,  Cu,    Nrf2/HO-1 Alleviates Disulfiram/Copper-Induced Ferroptosis in Oral Squamous Cell Carcinoma
- vitro+vivo, Oral, NA
AntiTum↑, TumCP↓, Ferroptosis↑, Iron↑, lipid-P↑, NRF2↓, HO-1↓,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,
1621- EA,    The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumMeta↓, TumCI↓, TumAuto↑, VEGFR2↓, MAPK↓, PI3K↓, Akt↓, PD-1↓, NOTCH↓, PCNA↓, Ki-67↓, cycD1/CCND1↓, CDK2↑, CDK6↓, Bcl-2↓, cl‑PARP↑, BAX↑, Casp3↑, DR4↑, DR5↑, Snail↓, MMP2↓, MMP9↓, TGF-β↑, PKCδ↓, β-catenin/ZEB1↓, SIRT1↓, HO-1↓, ROS↑, CHOP↑, Cyt‑c↑, MMP↓, OCR↓, AMPK↑, Hif1a↓, NF-kB↓, E-cadherin↑, Vim↓, EMT↓, LC3II↑, CIP2A↓, GLUT1↓, PDH↝, MAD↓, LDH↓, GSTs↑, NOTCH↓, survivin↓, XIAP↓, ER Stress↑, ChemoSideEff↓, ChemoSen↑,
3214- EGCG,    EGCG-induced selective death of cancer cells through autophagy-dependent regulation of the p62-mediated antioxidant survival pathway
- in-vitro, Nor, MRC-5 - in-vitro, Cerv, HeLa - in-vitro, Nor, HEK293 - in-vitro, BC, MDA-MB-231 - in-vitro, CRC, HCT116
mTOR↓, AMPK↑, selectivity↑, ROS↑, selectivity↑, HO-1↓, *NRF2↑, NRF2↓, *HO-1↑,
2514- H2,    Hydrogen: A Novel Option in Human Disease Treatment
- Review, NA, NA
*Inflam↓, *IL1β↓, *IL6↓, *IL8↓, *IL10↓, *TNF-α↓, *ROS↓, *HO-1↓, *NRF2↑, *ER Stress↓, H2O2↑,
1633- HCA,    Hydroxycitric Acid Alleviated Lung Ischemia-Reperfusion Injury by Inhibiting Oxidative Stress and Ferroptosis through the Hif-1α Pathway
- in-vivo, NA, NA - in-vitro, Nor, HUVECs
*other↓, *Inflam↓, *MDA↓, *ROS↓, *Iron↓, *SOD↓, *Hif1a↓, *HO-1↓,
2894- HNK,    Pharmacological features, health benefits and clinical implications of honokiol
- Review, Var, NA - Review, AD, NA
*BioAv↓, *neuroP↑, *BBB↑, *ROS↓, *Keap1↑, *NRF2↑, *Casp3↓, *SIRT3↑, *Rho↓, *ERK↓, *NF-kB↓, angioG↓, RAS↓, PI3K↓, Akt↓, mTOR↓, *memory↑, *Aβ↓, *PPARγ↑, *PGC-1α↑, NF-kB↓, Hif1a↓, VEGF↓, HO-1↓, FOXM1↓, p27↑, P21↑, CDK2↓, CDK4↓, CDK6↓, cycD1/CCND1↓, Twist↓, MMP2↓, Rho↑, ROCK1↑, TumCMig↓, cFLIP↓, BMPs↑, OCR↑, ECAR↓, *AntiAg↑, *cardioP↑, *antiOx↑, *ROS↓, P-gp↓,
2587- LT,    Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs
- in-vitro, Lung, A549
NRF2↓, GSH↓, ChemoSen↑, HO-1↓,
2588- LT,  Chemo,    Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway
- in-vitro, CRC, HCT116
NRF2↓, NQO1↓, HO-1↓, GSH↓, ChemoSen↑,
2589- LT,  Chemo,    Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway
- in-vitro, BC, MDA-MB-231
NRF2↓, HO-1↓, ChemoSen↑, CSCs↓, SIRT1↓,
2927- LT,    Luteolin Causes 5′CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells
- in-vitro, Cerv, HeLa
TumCMig↓, DNMTs↓, HDAC↓, HATs↓, ac‑H3↓, ac‑H4↓, MMP2↓, MMP9↓, HO-1↓, E-cadherin↑, EZH2↓, HER2/EBBR2↓, IL18↓, IL8↓, IL2↓,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
1204- MET,    Metformin induces ferroptosis through the Nrf2/HO-1 signaling in lung cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
MDA↑, ROS↑, Iron↑, GSH↓, T-SOD↓, Catalase↓, GPx4↓, xCT↓, NRF2↓, HO-1↓,
1770- PG,    Propyl gallate sensitizes human lung cancer cells to cisplatin-induced apoptosis by targeting heme oxygenase-1 for TRC8-mediated degradation
- in-vitro, Lung, NA
antiOx↑, Inflam↓, HO-1↓, eff↑, ChemoSen↑,
3077- RES,    Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways
- in-vitro, Chon, HTB94
MMP2↓, MMP9↓, SOX9↑, MMPs↓, p‑p38↑, p‑JNK↓, NF-kB↓, HO-1↓,
4908- Sal,    Salinomycin triggers prostate cancer cell apoptosis by inducing oxidative and endoplasmic reticulum stress via suppressing Nrf2 signaling
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
tumCV↓, ROS↑, lipid-P↑, UPR↑, ER Stress↑, NRF2↓, NADPH↓, HO-1↓, SOD↓, Catalase↓, GPx↓, eff↓, TumCP↓,
4726- Se,  Oxy,    Oxygen therapy accelerates apoptosis induced by selenium compounds via regulating Nrf2/MAPK signaling pathway in hepatocellular carcinoma
- in-vivo, HCC, NA
eff↝, NRF2↓, p‑p38↑, Apoptosis↑, eff↑, TumVol↓, other↝, toxicity↓, Dose↝, NRF2↝, HO-1↓, Catalase↓, SOD↓, e-pH↓, pH∅, MAPK↑, eff↑,
2132- TQ,    Thymoquinone treatment modulates the Nrf2/HO-1 signaling pathway and abrogates the inflammatory response in an animal model of lung fibrosis
- in-vivo, Nor, NA
*Weight∅, *antiOx↑, *lipid-P↓, *MMP7↓, *Casp3↓, *BAX↓, *TGF-β↓, *Diff↑, *NRF2↓, *HO-1↓, *NF-kB↓, *IκB↑,
3108- VitC,  QC,    The role of quercetin and vitamin C in Nrf2-dependent oxidative stress production in breast cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, Lung, A549
NRF2↓, HO-1↓, ROS↑, NRF2⇅,
2275- VitK2,    Delivery of the reduced form of vitamin K2(20) to NIH/3T3 cells partially protects against rotenone induced cell death
- in-vitro, Nor, NIH-3T3
*MMP↓, *ROS↓, *HO-1↓,

Showing Research Papers: 1 to 45 of 45

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 45

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 2,   antiOx↑, 1,   Catalase↓, 5,   Copper↑, 1,   CYP1A1↓, 1,   Fenton↑, 1,   Ferroptosis↑, 3,   GPx↓, 2,   GPx1↓, 2,   GPx4↓, 4,   GSH↓, 9,   GSR↓, 1,   GSTs↓, 1,   GSTs↑, 1,   H2O2↑, 2,   HO-1↓, 38,   HO-2↓, 1,   Iron↑, 3,   lipid-P↓, 1,   lipid-P↑, 3,   MAD↓, 1,   MDA↓, 2,   MDA↑, 3,   NQO1↓, 3,   NRF2↓, 24,   NRF2↑, 1,   NRF2⇅, 1,   NRF2↝, 1,   NRF2∅, 1,   OXPHOS↑, 1,   ROS↓, 1,   ROS↑, 23,   SOD↓, 4,   SOD↑, 1,   SOD1↑, 1,   SOD2↓, 3,   T-SOD↓, 1,   VitC↓, 1,   VitE↓, 1,   xCT↓, 2,  

Metal & Cofactor Biology ⓘ

Ferritin↓, 1,   Ferritin↑, 1,   FTH1↓, 1,   NCOA4↑, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 2,   ATP↑, 1,   CDC2↓, 1,   Insulin↓, 1,   MMP↓, 3,   MMP↑, 1,   OCR↓, 1,   OCR↑, 1,   XIAP↓, 6,  

Core Metabolism/Glycolysis ⓘ

ACSL4↑, 1,   ALAT↓, 1,   AMPK↑, 3,   cMyc↓, 1,   p‑cMyc↑, 1,   CRM↑, 1,   ECAR↓, 1,   ECAR↝, 1,   GlucoseCon↓, 1,   Glycolysis↓, 3,   HK2↓, 1,   lactateProd↓, 1,   LDH↓, 2,   LDL↓, 1,   NADPH↓, 2,   PDH↝, 1,   PDK1?, 2,   PDK1↓, 1,   PPARα↓, 1,   SIRT1↓, 4,   SIRT1↑, 1,   TCA↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 6,   Akt↑, 1,   p‑Akt↓, 3,   APAF1↑, 1,   Apoptosis↑, 8,   BAX↑, 5,   Bax:Bcl2↑, 2,   Bcl-2↓, 6,   Bcl-xL↓, 3,   Casp↑, 1,   Casp1↓, 1,   Casp3↓, 1,   Casp3↑, 6,   cl‑Casp3↑, 1,   Casp8↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 3,   cl‑Casp9↑, 1,   cFLIP↓, 1,   Cyt‑c↓, 1,   Cyt‑c↑, 5,   Diablo↑, 1,   DR4↑, 1,   DR5↑, 4,   Fas↑, 1,   FasL↑, 1,   Ferroptosis↑, 3,   HGF/c-Met↓, 1,   hTERT/TERT↓, 2,   iNOS↓, 4,   JNK↓, 1,   JNK↑, 3,   p‑JNK↓, 1,   p‑JNK↑, 1,   MAPK↓, 4,   MAPK↑, 2,   Mcl-1↓, 2,   MDM2↓, 2,   p‑MDM2↓, 1,   Myc↓, 1,   NICD↓, 1,   NOXA↑, 1,   p27↑, 4,   p38↑, 1,   p‑p38↑, 3,   PUMA↑, 1,   survivin↓, 4,   Telomerase↓, 2,   TumCD↑, 2,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

p‑CaMKII ↓, 1,   HER2/EBBR2↓, 1,   SOX9↑, 1,  

Transcription & Epigenetics ⓘ

EZH2↓, 1,   H3↓, 1,   ac‑H3↓, 1,   H4↓, 1,   ac‑H4↓, 1,   HATs↓, 1,   other↓, 1,   other↝, 1,   PhotoS↑, 1,   tumCV↓, 5,  

Protein Folding & ER Stress ⓘ

CHOP↑, 3,   p‑eIF2α↑, 2,   ER Stress↑, 4,   GRP78/BiP↑, 1,   HSP27↓, 1,   IRE1↑, 1,   PERK↑, 1,   UPR↑, 2,   XBP-1↓, 1,  

Autophagy & Lysosomes ⓘ

ATG3↑, 1,   ATG5↑, 1,   Beclin-1↑, 2,   LAMP2↑, 1,   LC3A↑, 1,   LC3B-II↑, 1,   LC3I↑, 1,   LC3II↑, 2,   p62↓, 1,   p62↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,   DNAdam↑, 6,   DNMTs↓, 1,   P53↓, 1,   P53↑, 7,   PARP↑, 3,   cl‑PARP↑, 4,   PCNA↓, 2,   SIRT6↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 4,   CDK2↑, 1,   CDK4↓, 1,   Cyc↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 6,   cycE/CCNE↓, 1,   P21↑, 6,   p‑RB1↓, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State ⓘ

CD34↓, 1,   CD44↓, 2,   CDK8↓, 1,   cFos↑, 1,   CIP2A↓, 1,   CSCs↓, 2,   Diff↑, 1,   EMT↓, 7,   ERK↓, 6,   p‑ERK↓, 1,   FOXM1↓, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 4,   IGF-1↓, 3,   mTOR↓, 5,   p‑mTOR↓, 1,   Nanog↓, 1,   NOTCH↓, 3,   NOTCH1↓, 2,   NOTCH1↑, 1,   OCT4↓, 1,   PI3K↓, 5,   p‑PI3K↓, 1,   PTEN↓, 1,   PTEN↑, 2,   RAS↓, 2,   SOX2↓, 1,   p‑Src↓, 1,   STAT3↓, 4,   p‑STAT3↓, 1,   STAT5↓, 1,   p‑STAT6↓, 1,   TAZ↓, 1,   TOP1↓, 1,   TumCG↓, 8,   Wnt↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

AEG1↓, 1,   AXL↓, 1,   Ca+2↑, 3,   Ca+2↝, 1,   CAFs/TAFs↓, 1,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 2,   E-cadherin↓, 1,   E-cadherin↑, 5,   FAK↓, 1,   p‑FAK↓, 1,   Fibronectin↓, 1,   ITGB1↓, 1,   Ki-67↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP-10↓, 1,   MMP2↓, 10,   MMP9↓, 8,   MMPs↓, 1,   N-cadherin↓, 3,   PKCδ↓, 2,   Rac1↓, 1,   Rho↓, 1,   Rho↑, 1,   ROCK1↓, 2,   ROCK1↑, 1,   Slug↓, 1,   Smad1↑, 1,   SMAD3↓, 1,   Snail↓, 6,   TET1↑, 1,   TGF-β↓, 1,   TGF-β↑, 2,   TIMP1↑, 1,   TIMP2↑, 1,   Treg lymp↓, 1,   TumCI↓, 5,   TumCMig↓, 7,   TumCP↓, 9,   TumMeta↓, 3,   Twist↓, 4,   Tyro3↓, 1,   Vim↓, 5,   Vim↑, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   EGFR↓, 2,   EGFR↑, 1,   Endoglin↑, 1,   Hif1a↓, 5,   VEGF↓, 7,   VEGFR2↓, 2,  

Barriers & Transport ⓘ

GLUT1↓, 1,   NHE1↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   CLP↑, 1,   COX1↓, 1,   COX2↓, 4,   COX2↑, 1,   CXCR4↓, 1,   ICAM-1↓, 1,   IFN-γ↓, 2,   IKKα↓, 2,   IL10↓, 1,   IL18↓, 1,   IL1β↓, 1,   IL2↓, 2,   IL2↑, 1,   IL4↓, 1,   IL6↓, 3,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 2,   JAK↓, 1,   JAK↝, 1,   JAK2↓, 1,   M2 MC↓, 1,   NF-kB↓, 8,   NF-kB↑, 1,   p‑NF-kB↑, 1,   p65↓, 1,   p‑p65↓, 2,   PD-1↓, 2,   PD-L1↓, 3,   PGE2↓, 1,   TILs↑, 1,   TLR4↓, 1,   TNF-α↓, 2,  

Cellular Microenvironment ⓘ

pH∅, 1,   e-pH↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,   CDK6↓, 4,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 2,   ChemoSen↓, 1,   ChemoSen↑, 17,   Dose↝, 4,   Dose∅, 1,   eff↓, 3,   eff↑, 17,   eff↝, 1,   MDR1↓, 1,   MRP1↓, 1,   RadioS↑, 10,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AR↓, 2,   BG↓, 1,   BMPs↑, 1,   CEA↓, 1,   EGFR↓, 2,   EGFR↑, 1,   EZH2↓, 1,   Ferritin↓, 1,   Ferritin↑, 1,   FOXM1↓, 1,   GutMicro↑, 2,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 2,   IL6↓, 3,   Ki-67↓, 1,   LDH↓, 2,   Myc↓, 1,   NSE↓, 1,   PD-L1↓, 3,  

Functional Outcomes ⓘ

AntiCan↑, 2,   AntiTum↑, 3,   cachexia↓, 1,   cardioP↑, 2,   chemoP↑, 3,   ChemoSideEff↓, 3,   neuroP↑, 1,   radioP↑, 1,   RenoP↑, 1,   toxicity↓, 1,   toxicity↝, 1,   TumVol↓, 2,  

Infection & Microbiome ⓘ

CD8+↑, 2,  
Total Targets: 360

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 4,   Catalase↑, 3,   Ferroptosis↓, 1,   GPx↑, 3,   GSH↑, 3,   GSTs↑, 2,   HDL↑, 1,   HO-1↓, 7,   HO-1↑, 2,   Iron↓, 1,   Keap1↓, 1,   Keap1↑, 1,   lipid-P↓, 3,   MDA↓, 3,   NRF2↓, 1,   NRF2↑, 5,   ROS↓, 8,   SIRT3↑, 1,   SOD↓, 1,   SOD↑, 4,   SOD1↑, 2,   TAC↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis ⓘ

glucose↝, 1,   GLUT2↑, 1,   HMG-CoA↓, 1,   PPARγ↑, 1,  

Cell Death ⓘ

BAX↓, 1,   Casp3↓, 5,   Casp9↓, 1,   Fas↓, 1,   Ferroptosis↓, 1,   HGF/c-Met↑, 1,   iNOS↓, 2,   MAPK↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↓, 1,   GRP78/BiP↑, 1,   GRP94↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

Diff↑, 1,   ERK↓, 1,   p‑ERK↑, 1,  

Migration ⓘ

AntiAg↑, 1,   MMP7↓, 1,   Rho↓, 1,   TGF-β↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IL10↓, 1,   IL10↑, 1,   IL1β↓, 3,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 4,   IκB↑, 1,   NF-kB↓, 4,   TLR4↓, 2,   TNF-α↓, 3,  

Protein Aggregation ⓘ

AGEs↓, 1,   Aβ↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 2,   BioAv↝, 1,   eff↑, 3,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

AST↓, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   chemoP↑, 1,   cognitive↓, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 2,   Pain↓, 1,   RenoP↑, 1,   toxicity↓, 2,   Weight∅, 1,   Wound Healing↑, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 1,   Diar↓, 1,  
Total Targets: 84

Scientific Paper Hit Count for: HO-1, HMOX1
6 Luteolin
5 diet FMD Fasting Mimicking Diet
4 Chemotherapy
3 Chrysin
3 Vitamin C (Ascorbic Acid)
2 doxorubicin
2 Artemisinin
2 Berbamine
2 Berberine
2 Chlorogenic acid
2 Ellagic acid
1 Allicin (mainly Garlic)
1 Alpha-Lipoic-Acid
1 Cisplatin
1 Baicalein
1 Radiotherapy/Radiation
1 Betulinic acid
1 Brucea javanica
1 brusatol
1 Bromelain
1 Curcumin
1 diet Short Term Fasting
1 Dipyridamole
1 Disulfiram
1 Copper and Cu NanoParticles
1 EGCG (Epigallocatechin Gallate)
1 Hydrogen Gas
1 HydroxyCitric Acid
1 Honokiol
1 Metformin
1 Propyl gallate
1 Resveratrol
1 salinomycin
1 Selenium
1 Oxygen, Hyperbaric
1 Thymoquinone
1 Quercetin
1 Vitamin K2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:597  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page